Who Exports Ciprofloxacin from India — 1001 Suppliers Behind a $301.1M Market
India's ciprofloxacin export market is supplied by 1001 active exporters who collectively shipped $301.1M across 14,146 shipments. DR.REDDY'S LABORATORIES LTD leads with a 16.1% market share, followed by SUN PHARMACEUTICAL INDUSTRIES LIMITED and DR REDDYS LABORATORIES LIMITED. The top 5 suppliers together control 45.9% of total export value, reflecting a moderately competitive market structure.
Top Ciprofloxacin Exporters from India — Ranked by Export Value
DR.REDDY'S LABORATORIES LTD is the leading ciprofloxacin exporter from India, holding a 16.1% share of the $301.1M market across 14,146 shipments from 1001 exporters. The top 5 suppliers — DR.REDDY'S LABORATORIES LTD, SUN PHARMACEUTICAL INDUSTRIES LIMITED, DR REDDYS LABORATORIES LIMITED, MACLEODS PHARMACEUTICALS LTD, AUROBINDO PHARMA LTD — collectively control 45.9% of total export value, indicating a competitive market. Individual shares are: DR.REDDY'S LABORATORIES LTD (16.1%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (12.0%), DR REDDYS LABORATORIES LIMITED (9.8%), MACLEODS PHARMACEUTICALS LTD (4.1%), AUROBINDO PHARMA LTD (3.8%).
Top Ciprofloxacin Exporters from India
Ranked by export value · 1001 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | DR.REDDY'S LABORATORIES LTD CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1CIPROFLOXACIN AND DEXAMETHASONE STERILE OTIC SUSPENSION USPCIPROFLOXACIN TABLETS USP 500 MG BATCH N | $48.5M | 3 | 16.1% |
| 2 | SUN PHARMACEUTICAL INDUSTRIES LIMITED CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1CIPROFLOXACIN TABLETS USP 250MG(12000 XCIPROFLOXACIN TABLETS BP (3 | $36.3M | 19 | 12.0% |
| 3 | DR REDDYS LABORATORIES LIMITED CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1CIPROFLOXACIN 500 MG TABLETS 10X10SCIPROFLOXACIN TABLETS USP 250MG(12000 X | $29.6M | 1 | 9.8% |
| 4 | MACLEODS PHARMACEUTICALS LTD CIPROFLOXACIN 500 MG TABLETS 10X10SAXOFLOX-500 (CIPROFLOXACIN TABLETS BP 50MICROLUSS (CIPROFLOXACIN TABLETS USP 500 | $12.5M | 8 | 4.1% |
| 5 | AUROBINDO PHARMA LTD CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1CIPROFLOXACIN TABLETS USP 250MG(12000 XCIPROFLOXACIN AND DEXAMETHASONE STERILE OTIC SUSPENSION USP | $11.4M | 13 | 3.8% |
| 6 | SENTISS PHARMA PRIVATE LIMITED | $9.2M | 7 | 3.1% |
| 7 | MEDOPHARM CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1CIPROFLOXACIN TABLETS USP 250MG(12000 XCIPROSCOT-500 BL. CIPROFLOXACIN | $6.7M | 19 | 2.2% |
| 8 | V S INTERNATIONAL PRIVATE LIMITED CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1CIPROFLOXACIN 500 MG TABLETS 10X10SCIPROFLOXACIN TABLETS USP 250MG(12000 X | $5.4M | 4 | 1.8% |
| 9 | J B CHEMICALS AND PHARMACEUTICALS LIMITED CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1CIPROFLOXACIN TABLETS USP 250MG(12000 XCIPROFLOXACIN TABLETS BP (3 | $5.3M | 7 | 1.8% |
| 10 | MEDNEXT BIOTECH LIMITED CIPROFLOXACIN TABLETS BP 500MGEACH FILM | $5.3M | 4 | 1.7% |
| 11 | FDC LIMITED CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1CIPROSCOT-500 BL. CIPROFLOXACINCIPROFLOXACIN TABLETS 500MG (WHITE,ELONG | $4.8M | 6 | 1.6% |
| 12 | DR.REDDY'S LABORATORIES LIMITED CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1CIPROFLOXACIN AND DEXAMETHASONE STERILE OTIC SUSPENSION USPCIPROFLOXACIN TABLETS USP 500 MG BATCH N | $4.5M | 2 | 1.5% |
| 13 | SUN PHARMACEUTICAL INDUSTRIES LTD CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1CIPROFLOXACIN TABLETS USP 250MG(12000 XCIPROFLOXACIN TABLETS BP (3 | $4.4M | 7 | 1.5% |
| 14 | BRAWN LABORATORIES LIMITED CIPROFLOXACIN 500 MG TABLETS 10X10SCIPROFLOXACIN TABLETS BP (3AXOFLOX-500 (CIPROFLOXACIN TABLETS BP 50 | $4.4M | 12 | 1.5% |
| 15 | MICRO LABS LIMITED CIPROFLOXACIN 500 MG TABLETS 10X10SAXOFLOX-500 (CIPROFLOXACIN TABLETS BP 50MICROLUSS (CIPROFLOXACIN TABLETS USP 500 | $4.2M | 11 | 1.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Ciprofloxacin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Dr. Reddy's Laboratories Ltd. | Approved | Yes | Yes | Multiple | FDA warning letter issued on September 12, 2025, for Biologics Facility. |
| Sun Pharmaceutical Industries Limited | Approved | Yes | Yes | Multiple | No recent FDA warning letters found. |
| Macleods Pharmaceuticals Ltd. | Approved | Yes | Yes | Multiple | No recent FDA warning letters found. |
| Aurobindo Pharma Ltd. | Approved | Yes | Yes | Multiple | No recent FDA warning letters found. |
| Micro Labs Limited | Approved | Yes | Yes | Multiple | No recent FDA warning letters found. |
TransData Nexus reviewed the regulatory standing of 5 leading Ciprofloxacin exporters from India. 5 hold US FDA facility approvals, 5 maintain WHO-GMP certification, and 5 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Ciprofloxacin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of Active Pharmaceutical Ingredients (APIs), including Ciprofloxacin. The city hosts numerous manufacturing facilities that focus on the synthesis of APIs, supplying both domestic and international markets. Companies like Dr. Reddy's Laboratories Ltd., headquartered in Hyderabad, have significantly contributed to the city's prominence in bulk drug manufacturing. Dr. Reddy's Laboratories Ltd. accounted for $48.5 million in Ciprofloxacin exports, representing 16.1% of the total exports in this category.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its expertise in pharmaceutical formulations. This region is home to several leading pharmaceutical companies that specialize in the development and production of finished dosage forms of drugs, including Ciprofloxacin tablets and injectables. Sun Pharmaceutical Industries Limited, based in this region, exported Ciprofloxacin worth $36.3 million, accounting for 12.0% of the total exports. Another key player, Macleods Pharmaceuticals Ltd., contributed $12.5 million, representing 4.1% of the total Ciprofloxacin exports.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for pharmaceutical products. This region's strategic location and well-developed port infrastructure facilitate the efficient export of pharmaceuticals to global markets. Companies like Cipla, headquartered in Mumbai, leverage this advantage to distribute their products worldwide. Cipla is among the top pharmaceutical exporters from India, contributing significantly to the country's pharmaceutical exports.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, primarily due to favorable tax incentives offered by the government. This area attracts numerous pharmaceutical companies that produce a wide range of medicines, including antibiotics like Ciprofloxacin. The tax benefits and supportive infrastructure have made Baddi-Nalagarh a preferred destination for pharmaceutical manufacturing.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different pharmaceutical clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and compliance records of suppliers, especially those in Hyderabad for APIs and Ahmedabad-Vadodara for formulations.
- Leverage Export Infrastructure: Utilize the export facilities in the Mumbai-Thane-Raigad region to ensure efficient and timely delivery of products to international markets.
- Consider Cost Advantages: Explore sourcing from the Baddi-Nalagarh region to benefit from potential cost savings due to tax incentives and lower operational costs.
By strategically sourcing from these diverse pharmaceutical clusters, companies can optimize their supply chain for Ciprofloxacin, ensuring quality, cost-effectiveness, and reliability.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Ciprofloxacin exporters from India
Aurobindo Pharma Ltd. — Aurobindo Pharma acquires Portugal's Generis for €135 million
Aurobindo Pharma Ltd. acquired Generis Farmaceutica SA from Magnum Capital Partners for €135 million, expanding its European footprint. IMPACT: This acquisition is expected to enhance Aurobindo's Ciprofloxacin export capabilities to European markets.
Impact: This acquisition is expected to enhance Aurobindo's Ciprofloxacin export capabilities to European markets.
Aurobindo Pharma Ltd. — Aurobindo signs agreement to acquire Apotex's businesses in five European countries
Aurobindo Pharma Ltd. signed a definitive agreement to purchase Apotex's businesses in Poland, the Czech Republic, the Netherlands, Spain, and Belgium, pending competition clearances. IMPACT: This acquisition is anticipated to strengthen Aurobindo's Ciprofloxacin distribution network across Europe.
Impact: This acquisition is anticipated to strengthen Aurobindo's Ciprofloxacin distribution network across Europe.
Aurobindo Pharma Ltd. — Aurobindo Pharma acquires Actavis' European operations for $41 million
Aurobindo Pharma Ltd. acquired the generic operations of Actavis in seven Western European countries, enhancing its presence in the European market. IMPACT: This acquisition likely bolstered Aurobindo's Ciprofloxacin export potential to Western Europe.
Impact: This acquisition likely bolstered Aurobindo's Ciprofloxacin export potential to Western Europe.
Common Questions — Ciprofloxacin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which ciprofloxacin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, DR.REDDY'S LABORATORIES LTD leads with 54 recorded shipments worth $48.5M. SUN PHARMACEUTICAL INDUSTRIES LIMITED (407 shipments) and DR REDDYS LABORATORIES LIMITED (22 shipments) are also established high-volume exporters.
Q How many ciprofloxacin manufacturers are there in India?
India has 1001 active ciprofloxacin exporters with a combined export market of $301.1M across 14,146 shipments to 180 countries. The top 5 suppliers hold 45.9% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for ciprofloxacin from India?
Average FOB unit price: $14.17 per unit, ranging from $0.00 to $10480.89. Average shipment value: $21.3K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 1001 verified Indian exporters of Ciprofloxacin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 14,146 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 180 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
14,146 Verified Shipments
1001 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists